Incretin hormone mimetics and analogues in diabetes therapeutics

被引：83

作者：

Green, Brian D. ^{[1
]}

Flatt, Peter R. ^{[2
]}

机构：

[1] Queens Univ Belfast, Sch Biol Sci, Belfast BT6 0NJ, Antrim, North Ireland

[2] Univ Ulster, Sch Biomed Sci, Coleraine BT52 1SA, Londonderry, North Ireland

来源：

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM | 2007年 / 21卷 / 04期

关键词：

incretin; glucagon-like peptide-1; glucose-dependent insulinotropic polypeptide; insulin; type-2; diabetes; glucose homeostasis; exendin;

D O I：

10.1016/j.beem.2007.09.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The incretin hormones glucagon-like peptide-I (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are physiological gut peptides with insulin-releasing and extrapancreatic glucoregulatory actions. Incretin analogues/mimetics activate GLP-I or GIP receptors whilst avoiding physiological inactivation by dipeptidyl peptidase 4 (DPP-4), and they represent one of the newest classes of antidiabetic drug. The first clinically approved GLP-1 mimetic for the treatment of type-2 diabetes is exenatide (Byetta/exendin) which is administered subcutaneously twice daily. Clinical trials of liraglutide, a GLP-1 analogue suitable for once-daily administration, are ongoing. A number of other incretin molecules are at earlier stages of development. This review discusses the various attributes of GLP-1 and GIP for diabetes treatment and summarises current clinical data. Additionally, it explores the therapeutic possibilities offered by preclinical agents, such as non-peptide GLP-1 mimetics, GLP-1/glucagon hybrid peptides, and specific GIP receptor antagonists.

引用

页码：497 / 516

页数：20

共 107 条

[11] A radioimmunoassay for LY315902, an analog of glucagon-like insulinotropic peptide, and its application in the study of canine pharmacokinetics [J].

Chou, JZ ;

Place, GD ;

Waters, DG ;

Kirkwood, JA ;

Bowsher, RR .

JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (07) :768-773

[12] Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes [J].

Claus, Thomas H. ;

Pan, Clark Q. ;

Buxton, Joanne M. ;

Yang, Ling ;

Reynolds, Jennifer C. ;

Barucci, Nicole ;

Burns, Michael ;

Ortiz, Astrid A. ;

Roczniak, Steve ;

Livingston, James N. ;

Clairmont, Kevin B. ;

Whelan, James P. .

JOURNAL OF ENDOCRINOLOGY, 2007, 192 (02) :371-380

[13]

Clements RH, 2004, AM SURGEON, V70, P1

[14] Exenatide blocks JAK1-STAT1 in pancreatic beta cells [J].

Couto, Francesca M. ;

Minn, Alexandra H. ;

Pise-Masison, Cynthia A. ;

Radonovich, Mike ;

Brady, John N. ;

Hanson, Matthew ;

Fernandez, Luis A. ;

Wang, Ping ;

Kendziorski, Christina ;

Shalev, Anath .

METABOLISM-CLINICAL AND EXPERIMENTAL, 2007, 56 (07) :915-918

[15]

Creutzfeldt M, 1974, Gastroenterology, V67, P748

[16] Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients [J].

Creutzfeldt, WOC ;

Orskov, C ;

Kleine, N ;

Holst, JJ ;

Willms, B ;

Nauck, MA .

DIABETES CARE, 1996, 19 (06) :580-586

[17] GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations [J].

Deacon, Carolyn F. ;

Plamboeck, Astrid ;

Rosenkilde, Mette M. ;

de Heer, Jocelyn ;

Holst, Jens J. .

AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2006, 291 (03) :E468-E475

[18] Circulation and degradation of GIP and GLP-1 [J].

Deacon, CF .

HORMONE AND METABOLIC RESEARCH, 2004, 36 (11-12) :761-765

[19] GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion [J].

Deacon, CF ;

Plamboeck, A ;

Moller, S ;

Holst, JJ .

AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2002, 282 (04) :E873-E879

[20] Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes [J].

DeFronzo, RA ;

Ratner, RE ;

Han, J ;

Kim, DD ;

Fineman, MS ;

Baron, AD .

DIABETES CARE, 2005, 28 (05) :1092-1100

← 1 2 3 4 5 6 7 8 9 10 →